» Articles » PMID: 24526547

Follow-up After Gastrectomy for Cancer: an Appraisal of the Italian Research Group for Gastric Cancer

Abstract

Background: The Italian Research Group for Gastric Cancer supports the practice of follow-up after radical surgery for gastric cancer.

Methods: This multicenter, retrospective study (1998-2009) included patients with T1-4N0-3M0 gastric cancer who had undergone D2 gastrectomy and lymphadenectomy, with at least 15 lymph nodes examined, and who had developed recurrent disease. Timing and site of recurrence were correlated to the actual scheduled follow-up timing and modalities.

Results: From eight centers, 814 patients with recurrent cancer and over 1,754 (46.4 %) patients undergoing gastrectomy were investigated (median follow-up 31 months). The most frequent sites of recurrence were local/regional lymph nodes (35.4 %), liver (24.3 %), peritoneum (30.3 %), lung (10.4 %) and intraluminal (7.5 %). Ninety-four percent of the recurrences were diagnosed within 2 years and 98 % within 3 years. Thoracoabdominal computed tomography (CT) scan and (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (18-FDG-PET) detected more than 90 % of recurrences, abdominal ultrasound detected 70 % and tumor markers detected 40 %, while <10 % were identified by physical examination, chest X-ray, and upper gastrointestinal endoscopy. Twenty-six percent of patients with recurrence were treated, but only 3.2 % were treated with potentially radical intent.

Conclusion: Oncological follow-up after radical surgery for gastric cancer should be focused in the first 3 years, and based mainly on thoracoabdominal CT scan and 18-FDG-PET.

Citing Articles

prescription for preventing and treating postoperative recurrence and metastasis of gastric cancer: a randomized controlled trial protocol.

Cao L, Zhu G, Wang X, Kuang Z, Song X, Ma X Front Oncol. 2024; 14:1326970.

PMID: 39035732 PMC: 11257841. DOI: 10.3389/fonc.2024.1326970.


Circulating tumor DNA predicts recurrence and assesses prognosis in operable gastric cancer: A systematic review and meta-analysis.

Mi J, Wang R, Han X, Ma R, Li H Medicine (Baltimore). 2023; 102(48):e36228.

PMID: 38050202 PMC: 10695564. DOI: 10.1097/MD.0000000000036228.


Efficacy of chemotherapy combined with surgical resection for gastric cancer with synchronous ovarian metastasis: A propensity score matching analysis.

Fang J, Huang X, Chen X, Xu Q, Chai T, Huang L Cancer Med. 2023; 12(16):17126-17138.

PMID: 37519112 PMC: 10501252. DOI: 10.1002/cam4.6362.


Prognostic Impact of Visceral Pleural Invasion in Resected Solitary Lung Metastases from Gastric Cancer.

Shigenobu T, Ohtsuka T, Hanawa R, Sakamaki H, Yoshizu A, Tajima A Ann Thorac Cardiovasc Surg. 2023; 29(6):279-286.

PMID: 37316253 PMC: 10767656. DOI: 10.5761/atcs.oa.23-00032.


Postoperative circulating tumor DNA detection and CBLB mutations are prognostic biomarkers for gastric cancer.

Zhou H, Liu H, Li J, Wang J, Fu X, Li Y Genes Genomics. 2023; 45(8):1037-1046.

PMID: 37306927 PMC: 10349697. DOI: 10.1007/s13258-023-01412-7.